JP2023531683A5 - - Google Patents

Info

Publication number
JP2023531683A5
JP2023531683A5 JP2022579019A JP2022579019A JP2023531683A5 JP 2023531683 A5 JP2023531683 A5 JP 2023531683A5 JP 2022579019 A JP2022579019 A JP 2022579019A JP 2022579019 A JP2022579019 A JP 2022579019A JP 2023531683 A5 JP2023531683 A5 JP 2023531683A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
patient
treatment
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022579019A
Other languages
English (en)
Japanese (ja)
Other versions
JP7880618B2 (ja
JP2023531683A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038264 external-priority patent/WO2021262604A2/en
Publication of JP2023531683A publication Critical patent/JP2023531683A/ja
Publication of JP2023531683A5 publication Critical patent/JP2023531683A5/ja
Application granted granted Critical
Publication of JP7880618B2 publication Critical patent/JP7880618B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022579019A 2020-06-21 2021-06-21 CEBP-βアンタゴニストの投与及び使用方法 Active JP7880618B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063041989P 2020-06-21 2020-06-21
US202063041986P 2020-06-21 2020-06-21
US202063041990P 2020-06-21 2020-06-21
US202063041991P 2020-06-21 2020-06-21
US202063041988P 2020-06-21 2020-06-21
US63/041,986 2020-06-21
US63/041,990 2020-06-21
US63/041,989 2020-06-21
US63/041,991 2020-06-21
US63/041,988 2020-06-21
US202163172560P 2021-04-08 2021-04-08
US63/172,560 2021-04-08
PCT/US2021/038264 WO2021262604A2 (en) 2020-06-21 2021-06-21 Administration of cebp-beta antagonist and methods of use

Publications (3)

Publication Number Publication Date
JP2023531683A JP2023531683A (ja) 2023-07-25
JP2023531683A5 true JP2023531683A5 (cg-RX-API-DMAC7.html) 2025-01-20
JP7880618B2 JP7880618B2 (ja) 2026-06-26

Family

ID=79281738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579019A Active JP7880618B2 (ja) 2020-06-21 2021-06-21 CEBP-βアンタゴニストの投与及び使用方法

Country Status (17)

Country Link
US (1) US20230218717A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168033B1 (cg-RX-API-DMAC7.html)
JP (1) JP7880618B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230027054A (cg-RX-API-DMAC7.html)
CN (1) CN115768458A (cg-RX-API-DMAC7.html)
AU (1) AU2021297172B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022025880A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180559A1 (cg-RX-API-DMAC7.html)
DK (1) DK4168033T3 (cg-RX-API-DMAC7.html)
ES (1) ES3066151T3 (cg-RX-API-DMAC7.html)
FI (1) FI4168033T3 (cg-RX-API-DMAC7.html)
IL (1) IL299104A (cg-RX-API-DMAC7.html)
MX (1) MX2022016478A (cg-RX-API-DMAC7.html)
NZ (1) NZ795026A (cg-RX-API-DMAC7.html)
PT (1) PT4168033T (cg-RX-API-DMAC7.html)
WO (1) WO2021262604A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202213167B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119997967A (zh) * 2022-10-07 2025-05-13 智慧疗法有限公司 C/EBP-β拮抗剂和免疫调节剂的使用
WO2024216238A2 (en) * 2023-04-13 2024-10-17 Sapience Therapeutics, Inc. Use of beta-catenin antagonist and immunomodulator
EP4694911A2 (en) * 2023-04-13 2026-02-18 Sapience Therapeutics, Inc. Administration of a beta-catenin antagonist and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228642A (zh) * 2013-02-22 2016-01-06 纽约市哥伦比亚大学理事会 通过抑制转录因子atf5来抑制肿瘤细胞的组合物和方法
CA2983030A1 (en) * 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
WO2018152446A2 (en) 2017-02-20 2018-08-23 Sapience Therapeutics, Inc. Cell-penetrating atf5 polypeptides and uses thereof
PT3737399T (pt) 2018-01-03 2023-09-04 Sapience Therapeutics Inc Variantes do péptido atf5 e as respetivas utilizações
WO2020033555A2 (en) * 2018-08-08 2020-02-13 The Trustees Of Columbia University In The City Of New York Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells

Similar Documents

Publication Publication Date Title
Krishnan et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177
Franke et al. Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review
JP6351597B2 (ja) 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤
Rochet et al. Melanoma brain metastases and vemurafenib: need for further investigation
Aquilanti et al. Immune checkpoint inhibitors for brain metastases: a primer for neurosurgeons
CN105916501A (zh) 用于治疗局部晚期或转移性雌激素受体阳性乳腺癌的雌激素受体调节剂
EP4168008B1 (en) A combination of belzutifan and lenvatinib for use in treating cancer
AU2021297172B2 (en) Administration of CEBPβ antagonist and methods of use
Gligorov et al. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer
US20210046106A1 (en) Methods of treating cancer with androgen deprivation therapy in combination with an inhibitor of the sp1 transcription factor
RU2858600C2 (ru) Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли
WO2020210829A1 (en) Methods of promoting long-term survival of patients with advanced chemotherapy-resistant malignancies
von Spreckelsen et al. DDIS-36. BTP-7, A NOVEL PEPTIDE FOR THERAPEUTIC TARGETING OF MALIGNANT BRAIN TUMORS
Shen et al. Changjun Wang1, Yan Lin1, Yidong Zhou1, Feng Mao1, Hanjiang Zhu2, Jinghong Guan1, Xiaohui Zhang1
WO2024077297A2 (en) Use of c/ebp-beta antagonist and immunomodulator
Buxton et al. RTID-11. GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
WO2025068348A1 (en) Pharmaceutical combination of cxcr4 and pd-1 inhibitors for treating cancer
HK40087480A (en) Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib
EP4694911A2 (en) Administration of a beta-catenin antagonist and methods of use
Akimoto et al. Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes
Shabaya et al. Novel therapeutic strategies and combinations for HER2-overexpressing breast cancer
Ray-Coquard et al. Methods: Eligible patients had high-grade PROC with≤ 4 prior lines of chemotherapy. Weekly paclitaxel (80 mg/m²) and increasing doses of ganetespib (100, 150 mg/m²) were given iv on days 1, 8, 15 in a 28 days cycle until disease progression or unacceptable toxicity. Endpoints were safety and determination of phase II dose. Dose limiting toxicity (DLT) was defined as grade 4 toxicity (with exceptions) occurring in cycles 1&2.